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Background: Pulmonary arterial hypertension (PAH) is a severe and progressive disease characterized by increased
pulmonary vascular resistance, ultimately leading to right heart failure and death. Epidemiological data from
national registries are growing worldwide, but are still unavailable in Eastern Europe.
Methods: A PAH registry was initiated in January 2007 using a nationwide network of echocardiographic centers
and four diagnostic centers that specialize in PAH. All patients aged above 18 years, diagnosed with PAH and
monitored between January 2000 and December 2007 were included. Patients diagnosed with PAH between
January and December 2007 were classified as incident. The survival analyses were performed up to the end of
2010. Prognostic factors at the time of diagnosis were identified using uni- and multivariable Cox proportional
hazard models.
Results: Overall, 191 patients were included (100 prevalent cases, 91 incident cases). Patients were predominantly
female (n = 125) and had a mean age of 51.9 ± 16.9 years. Incident patients were significantly older at the time of
diagnosis than prevalent patients (p < 0.001). Most patients (60.7%) had idiopathic PAH; 20.4% had PAH associated
with congenital heart disease and 11.4% had PAH associated with connective tissue disease. Estimates of prevalence
and incidence of PAH in adults were 22.4 cases per million and 10.7 cases per million per year, respectively. The 1-,
2- and 3-year survival rates in the incident PAH cohort were 89% (95% confidence intervals [CI] 83–95%), 78% (95% CI
70–87%) and 74% (95% CI 65–83%), respectively. Lower survival rates were significantly associated with higher age
(hazard ratio [HR] 6.6 95% CI 1.4–30.9) and lower creatinine clearance (HR 3.3 95% CI 1.1–9.7).
Conclusion: This is the first study in Eastern Europe to describe the prevalence, incidence and survival of patients with
PAH from a national representative registry. This registry from the Czech Republic highlights that diagnosis of PAH is
frequently made late in the disease continuum when patients have significant functional impairment.
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Pulmonary arterial hypertension (PAH) is a chronic, pro-
gressive and potentially fatal disease of the pulmonary
vasculature that leads to heart failure. PAH is a clinical
condition characterized by the presence of pre-capillary
pulmonary hypertension. It is defined as an increase in
mean pulmonary arterial pressure (PAP) ≥25 mmHg at
rest in the absence of significantly elevated pulmonary
capillary wedge pressure (PCWP ≤15 mmHg) as assessed
by right heart catheterization (RHC) [1]. PAH is classi-
fied into a number of categories according to etiology
[1]. These are: idiopathic PAH, heritable, induced by ex-
posure to drugs and toxins, or associated with other
conditions such as connective tissue disease (APAH-
CTD) or congenital heart disease (APAH-CHD). At the
recent World Symposium on Pulmonary Hypertension
(PH [Nice 2013]) there were some suggestions to update
the classification of PH, for example, to classify patients
with hemolytic anemia into Group 5 [2]; in this paper
we have classified patients according to the current
guidelines.
Population-based estimates of PAH incidence and
prevalence are not available. However, as in other rare
diseases, patient registries provide valuable epidemio-
logical information about PAH [3]. Data from PAH
registries suggest estimates for PAH and idiopathic PAH
incidence of 2–8 and 1–2 cases per million population
per year, respectively [4-10]. The Orphanet 2012 report
estimates the prevalence of idiopathic PAH in Europe to
be about 6 per million population [11]. Based on infor-
mation collected in PAH registries, prevalence estimates
of PAH and idiopathic PAH range between 15 to 26
cases per million adults and 6 to 9 cases per million
adults, respectively [4-10].
The data from the US National Institutes of Health
(NIH) registry over 20 years ago provided the first esti-
mates of survival rates in PAH and showed that the me-
dian survival rate was 2.8 years after diagnosis [12].
Several treatment options have become available for
management of PAH since the NIH registry was pub-
lished. In the Czech Republic epoprostenol became
available in 2000, followed by treprostinil, iloprost and
bosentan in 2003, sildenafil in 2006 and ambrisentan be-
came available in 2011. Until 2006 the use of PAH-
specific drugs in the Czech Republic was restricted to a
limited number of patients. Since 2006 PAH-specific
therapy is prescribed in specialist centers in the Czech
Republic with no restriction on the number of patients
who can receive therapy. However, despite clear im-
provements in patient outcomes, the disease remains in-
curable [5].
To date, national registries for PAH are limited to the
USA, Western Europe, China and Australia [3]. The only
available epidemiology data about PAH in the CzechRepublic have been from a retrospective analysis of the
number of patients diagnosed in cardiology and pneu-
mology clinics during the period 1980–1999 [13]. Since
then an effective network of echocardiographic and PAH
expert centers has been developed. The objectives of the
current study were to estimate the prevalence and inci-
dence of PAH in the Czech Republic, to describe the
clinical characteristics of patients with PAH included in
the national registry during the modern treatment era
and to estimate survival in a cohort of incident patients.
Prognostic factors for survival were also explored in the
cohort of incident PAH patients.
This study estimates the prevalence, incidence and long-
term survival of PAH patients in the Czech Republic.
Methods
Study design
A system of centralized care in four expert centers,
which share a unique data collection system, was set up
in 2000 in the Czech Republic. In 2007, this system was
extended to improve the detection of PAH by establish-
ing a network of referring echocardiographic laborator-
ies. Currently all patients in the Czech Republic with
PAH, as recognized during echocardiographic assess-
ment, have the final diagnosis confirmed by RHC in
one of the two specialized centers (Charles University,
1st Faculty of Medicine, 2nd Medical Department,
Clinical Department of Cardiology and Angiology,
Prague; Cardiology Center, Institute of Clinical and Ex-
perimental Medicine-IKEM, Department of Cardiology,
Prague, Czech Republic). Long-term follow-up is then
provided at either of the two specialized centers or at
two other expert centers (Na Homolce Hospital, Depart-
ment of Cardiac Surgery, Prague; University Hospital,
Brno Bohunice, Department of Cardiology, Brno).
In this retrospective analysis, all consecutive patients
aged ≥18 years with a diagnosis of Group 1 PAH made
either between January and December 2007 (incident
cases) or before January 2007 (prevalent cases) were in-
cluded. Of the patients diagnosed before 2007, only
those who survived to January 2007 were included in the
analysis. Patients diagnosed after 2007 were not included
in this study as access to the database information for all
centers diagnosing PAH was not available after 2007.
Patients were classified as having either idiopathic
PAH, heritable PAH, APAH-CTD, APAH-CHD or
‘other’ (‘other’ patients included patients with portal
hypertension or PAH associated with hemolytic anemia)
according to the 2009 international clinical classification
of pulmonary hypertension [1]. PAH was defined as
mean PAP ≥25 mmHg at rest and PCWP ≤15 mmHg.
All patients meeting the definition for PAH were eli-
gible for the analysis. Time of diagnosis was defined as
the date on which diagnosis by RHC was made. To be
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before study entry. Patients were ineligible if they were
aged under 18 years at the time of diagnosis. In order to
assess a homogenous population, patients with abnormal
ventilation parameters (forced vital capacity, total lung
capacity or forced expiratory volume in 1 second <60% of
normal values [14]) and patients with significant left heart
disease (recognized as left ventricular ejection fraction
<50% and significant left-sided valvular disease) were
excluded from the analysis. Patients with chronic
thromboembolic pulmonary hypertension identified using
ventilation-perfusion scintigraphy were also excluded.
An acute vasodilator challenge was performed during
RHC to assess vasoreactivity. This was assessed by
administration of an intravenous synthetic prostacyclin
analog. A positive test was defined as a drop in mean PAP
greater than 10 mmHg leading to a value <40 mmHg
without a decrease in cardiac output.
Clinical, hemodynamic and pulmonary parameters
were recorded at the time of diagnosis. A functional as-
sessment of 6-minute walk distance (6MWD) and New
York Heart Association (NYHA) functional class was
also conducted. The time between start of symptoms
(information provided by the patient) and diagnosis was
assessed.
Analysis
Standard descriptive statistics were applied in the analysis.
Mean ± standard deviation (SD) or median (interquartile
and 5th–95th percentile ranges) were used to describe
continuous parameters. Comparisons between groups of
patients were performed using Mann–Whitney U test for
continuous parameters. Categorical variables were de-
scribed by frequencies, and comparisons between groups
were performed using maximal likelihood chi-square test
of Fisher’s exact test. The limit of statistical significance
was set as p = 0.05.
Newly diagnosed patients (January 1 to December 31,
2007) were included for calculation of the incidence,
while all living patients by January 1, 2007 were used to
estimate prevalence. Rates were standardized per one
million adult persons using the National Czech census
data as a reference [15] with a 95% confidence interval
reported based on a Poisson distribution. The denomin-
ator of the population used to calculate incidence was
8,522,012 (the adult Czech population in 2007).
For the survival analysis, an endpoint of all-cause mor-
tality was used and patients were followed to their last
visit in 2010. Survival was estimated from time of diag-
nostic RHC to 6, 12, 18, 24 and 36 months post-
diagnosis using the Kaplan-Meier method and survival
curves compared with the log-rank test [16].
The relationship between potential prognostic vari-
ables measured at the time of diagnosis and mortalitywas assessed in the incidence cohort of patients with
idiopathic or heritable PAH using uni- and multivariable
Cox proportional hazard models. The selection of vari-
ables for the multivariable model was based on univari-
ate statistical significance <0.1 followed by redundancy
analysis using correlation analysis of predictors and a
forward stepwise algorithm.
Ethics committee approval
The study was discussed with the Ethics Committee of
the General University Hospital in Prague. As it is a
retrospective analysis of anonymized data from routine
clinical practice, Czech legislation does not require ap-
proval from an ethics committee.
Results
Patient population
Between January 2000 and December 2007, 191 patients
were diagnosed with PAH and included in the registry
(79.6% at the 2nd Department of Internal Medicine,
General University Hospital and 1st Medical Faculty of
Charles University, Prague and 20.4% at the Cardiology
Center, Institute for Clinical and Experimental Medicine,
Prague). Incident patients accounted for 47.7% (n = 91)
of all patients.
Overall, 65% (n = 125) of diagnosed patients were female
and the mean age of the population was 51.9 ± 16.9 years.
The majority of patients were diagnosed between the ages
of 51 and 70 years. The incident group was significantly
older at the time of diagnosis than the prevalent group
(p < 0.001). Baseline clinical, hemodynamic and pulmon-
ary parameters in the prevalent and incident groups are
shown in Table 1.
The most frequently diagnosed type of PAH was idio-
pathic (60.7%) followed by APAH-CHD (20.4%) and
then APAH-CTD (11.0%) (Table 2). Of the PAH-CHD
patients, 21 (53.8%) had Eisenmenger syndrome, four
had PAH with left-to-right uncorrectable shunts and 14
had post-operative PAH. The patients had various
defects: atrial septal defects (n = 11), ventricular septal
defect (n = 17), patent ductus arteriosus (n = 6) and
others (atrioventricular septal defect, truncus arteriosus
or aortopulmonary window [n = 5]). There was no sig-
nificant difference in the proportion of patients with
each etiology in the prevalent and incident groups. The
acute pulmonary vasoreactivity test, conducted in all pa-
tients was positive in 3.1% of patients (n = 6): five cases
with idiopathic or heritable PAH and one case with
APAH-CTD. Vasoactive potential was not observed in
the other PAH etiologies.
Most of the patients (71.2%) were in NYHA functional
class III or IV at the time of diagnosis. This is reflected
in the patients’ treatments – nearly all patients were re-
ceiving treatment with PAH-specific therapies, and the
Table 1 Clinical, hemodynamic and pulmonary parameters in the prevalent and incident populations
Prevalent cases n = 100 Incident cases n = 91 p†
Female sex, n (%) 65 (65.0) 60 (65.9) 0.892
NYHA FC 0.229‡
I + II, n (%) 34 (34.0) 21 (23.1)
III, n (%) 64 (64.0) 67 (73.6)
IV, n (%) 2 (2.0) 3 (3.3)
Age* (years) 47.0 (17.0) 47.8 (34.5–60.7/19.4–73.8) 57.3 (15.1)† 59.8 (48.9–68.8/27.4–75.7) <0.001
BMI* (kg/m2) 26.2 (5.4) 26.0 (21.8–29.7/18.3–35.9) 27.8 (6.3) 26.5 (23.2–31.9/19.5–37.9) 0.100
6MWD* (m) 332.4 (123.0) 356.0 (246.0–420.0/150.0–511.0) 314.0 (117.0) 332.5 (239.0–403.0/128.0–474.0) 0.313
RAP* (mmHg) 10.0 (5.3) 9.0 (7.0–12.0/3.0–20.0) 9.8 (5.2) 9.0 (6.0–12.0/2.0–21.0) 0.934
mPAP* (mmHg) 65.8 (84.8) 56.5 (46.0–66.0/32.0–89.0) 51.8 (19.7)† 47.0 (37.0–64.0/27.0–91.0) 0.004
PASP* (mmHg) 88.2 (24.6) 91.0 (70.0–103.0/45.0–134.0) 80.7 (28.5)† 77.0 (58.0–97.0/40.0–132.0) 0.017
PCWP* (mmHg) 10.5 (3.2) 11.0 (8.0–13.0/5.0–15.0) 11.9 (3.1)† 12.0 (10.0–15.0/7.0–15.0) 0.003
Cardiac index* (l/min/m2) 1.9 (0.7) 1.7 (1.3–2.4/0.8–3.3) 2.4 (0.8)† 2.4 (1.9–2.9/1.1–3.9) <0.001
CO* (l/min) 3.4 (1.5) 3.2 (2.3–4.3/1.6–6.4) 4.3 (1.6)† 3.9 (3.2–5.4/2.1–7.1) <0.001
SvO2
* (%) 92.5 (5.5) 94.5 (90.2–96.4/78.0–98.1) 91.7 (6.8) 93.5 (89.9–96.2/79.0–98.0) 0.461
SvO2
* (%) 66.4 (7.5) 66.0 (61.0–72.0/55.8–78.7) 70.0 (8.6)† 72.0 (64.6–76.0/56.0–81.2) 0.002
LVEF* (%) 60.9 (8.4) 61.5 (55.0–67.0/46.0–74.0) 59.3 (7.5) 58.0 (55.0–64.0/45.0–72.0) 0.199
PAR* (WU) 20.1 (31.1) 16.0 (9.3–21.4/4.2–42.2) 10.8 (7.1)† 8.5 (5.6–15.2/3.0–25.8) <0.001
S-creatinine* (μmol/l) 95.3 (43.1) 88.7 (71.6–99.0/59.1–173.5) 97.2 (49.8) 81.2 (71.0–104.0/56.0–193.0) 0.895
Creatinine clearance* (ml/min) 90 (30) 84 (66–108/42–144) 78 (36) 78 (60–96/30–138) 0.186
NYHA, New York Heart Association; BMI, body mass index; 6MWD, 6-minute walk distance; RAP, resting arterial pressure; mPAP, mean pulmonary arterial pressure;
PASP, pulmonary artery systolic pressure; PCWP, pulmonary capillary wedge pressure; SaO2,oxygen saturation of arterial blood; SvO2, oxygen saturation of central
venous blood; LVEF, left ventricular ejection fraction; PAR, pulmonary arteriolar resistance; CO, cardiac output.
*Mean (SD), median (25th–75th/5th–95th percentile).
†Mann–Whitney U test for continuous parameters; maximal likelihood chi-square test or Fisher’s exact test for categorical parameters. ‡P-value represents
significance of NYHA FC between incident and prevalent cases.
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bosentan (Table 3). There was little difference between
the treatments in patients who were incident compared
with prevalent patients.
In the 156 patients with available data on the time of
symptom onset, the mean time from the manifestation
of symptoms until a confirmed diagnosis was 38.7 ±
47.7 months across the entire group, 36.4 ± 42.3 months
in idiopathic PAH patients, 52.0 ± 62.8 months in APAH-
CHD patients, 30.8 ± 45.8 months in APAH-CTD patients
and 50.8 ± 92.9 months in heritable PAH patients. TheTable 2 Proportion of PAH subtypes at time of diagnosis
PAH subtype All cases n = 191 Prevalent
Idiopathic, n (%) 116 (60.7) 67 (67.0)
Heritable, n (%) 7 (3.7) 3 (3.0)
APAH-CHD, n (%) 39 (20.4) 16 (16.0)
APAH-CTD, n (%) 21 (11.0) 12 (12.0)
Other†, n (%) 8 (4.2) 2 (2.0)
APAH-CHD, pulmonary arterial hypertension associated with congenital heart disea
tissue disease.
†Other PAH etiologies included: portal hypertension and PAH associated with hemo
*Difference between prevalent and incident cases maximal likelihood chi-square tesdifference in time from the manifestation of symptoms be-
tween the prevalent and incident cases was not statistically
significant (Table 4). Median follow up time after inclusion
in the registry was 38 months.
Incidence and prevalence
The estimated incidence of PAH in adults in the Czech
Republic was 10.7 cases per million persons overall in
2007 (7.5 per million men and 13.7 per million women).
The incidence of idiopathic/heritable PAH was 6.2 per
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lytic anemia.
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Combination therapy 11 26
Bosentan + sildenafil 3 14
Bosentan + iloprost 2 -
Sildenafil + iloprost 2 2
Sildenafil + treprostinil 2 4
Sildenafil + epoprostenol 2 4
Epoprostenol + sildenafil + bosentan - 2
Investigational drugs 7 5
No specific therapy 4 5
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Czech adult population was 22.4 cases per million
persons overall (16 per million men and 28.5 per
million women). The estimated prevalence of idio-
pathic/heritable PAH was 14.4 per million persons
overall (11.1 per million men and 17.5 per million
women).Table 4 Time from appearance of first PAH symptoms and di
PAH subtype Time between first symptoms and
Total (n = 156) Preval
Idiopathic
Mean (SD) 36 (42) 36 (42)
Median (25th-75th; 5th-95th) 23 (10–49/2–120) 22 (7–4
APAH-CHD
Mean (SD) 52 (63) 31 (45)
Median (25th-75th; 5th-95th) 24 (8–96/0–251) 21 (2–2
APAH-CTD
Mean (SD) 31 (46) 47 (59)
Median (25th-75th; 5th-95th) 12 (8–24/2–192) 24 (12–
Heritable
Mean (SD) 51 (93) 15 (13)
Median (25th-75th; 5th-95th) 13 (10–24/5–240) 15 (5–2
Total
Mean (SD) 39 (48) 36 (43)
Median (25th-75th; 5th-95th) 24 (10–49/1–120) 22 (8–4
APAH-CHD, pulmonary arterial hypertension associated with congenital heart disea
tissue disease.
*Difference between prevalent and incident cases Mann–Whitney U test.Survival of incident PAH patients
In the incident population, the 1-, 2- and 3-year survival
rates were 89%, 78% and 74%, respectively (Figure 1A).
When the subgroup of patients with idiopathic/heritable
PAH was analyzed, the 1-, 2- and 3-year survival rates
were 85%, 70% and 62%, respectively (Figure 1B). For
the APAH-CHD subgroup, survival rates were 100%,
100% and 96%, respectively (Figure 1B).
The univariate analysis of the incident group of PAH pa-
tients revealed significantly shorter survival rates in patients
>60 years of age (hazard ratio and 95% confidence intervals
[HR 95% CI] 5.5 [2.1, 14.8], p < 0.001), 6MWD ≤290 m
(HR 3.4 [1.4, 8.2], p = 0.007), PCWP >12 mmHg (HR 2.4
[1.0, 5.5], p = 0.046) or with creatinine clearance ≤66 ml/
min (HR 3.8 [1.4, 10.3], p = 0.008) (Figure 2A). The majority
of these factors were also associated with shorter survival
rates in a subgroup of incident patients with idiopathic/her-
itable PAH; the only exception being age (HR [95% CI] 2.8
[1.0, 7.6], p = 0.049) (Figure 2B). The other factors investi-
gated had no significant influence on survival. The multi-
variate analysis of the incident group of PAH patients
revealed significantly shorter survival rates in patients
>60 years of age (HR 6.6 (1.4; 30.9), p = 0.016) or with cre-
atinine clearance ≤66 ml/min (HR 3.3 (1.1; 9.7), p = 0.027).
It was generally observed that in patients with idiopathic/
heritable PAH and S-creatinine levels ≤90 mg/dl, that right
atrial pressure was significantly lower when compared with
S-creatinine >90 mg/dl (mean 5.8/median 5 vs mean 10.5/
median 8, p = 0.013 – Mann–Whitney U test).agnosis
diagnosis (months)











se; APAH-CTD, pulmonary arterial hypertension associated with connective
Figure 1 Overall survival in the incident population. A) All patients with PAH; B) Patients with idiopathic or heritable PAH (n = 53) or
APAH-CHD (n = 23).
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Our registry data estimated the annual incidence of PAH
in the Czech adult population as 10.7 per million persons
and the prevalence as 22.4 per million persons. The inci-
dence rate is higher than the range of 2–8 per million re-
ported by other registries while the prevalence is in the
range previously reported [4-10]. The higher number of
newly diagnosed incident cases in 2007 was confirmed by
high diagnosis rates in the following years: The General
University Hospital, Prague diagnosed 70 patients in 2008
and 63 patients in 2009 (P Jansa, personal communication,
2014). The number of newly diagnosed patients in 2007
(and in 2008 and 2009) compared with 2000–2006, couldbe explained by a higher referral rate after 2006, due to
the wider availability of PAH-specific drugs after 2006.
This high number of incident cases might also be ex-
plained by an efficient system for referring patients with
suspected PAH, in a country with a relatively small popu-
lation. The annual incidence of idiopathic and heritable
PAH was 6.2 per million persons and the prevalence was
14.4 per million. Our results highlight that PAH remains a
rare disease in Eastern Europe.
Patient characteristics of the Czech population
Idiopathic/heritable PAH accounted for the majority of
diagnoses (64%), while rates of APAH-CHD and APAH-
Figure 2 Factors associated with survival in the incident population. A) All patients (n = 91); B) Patients with idiopathic or heritable PAH
(n = 53). Footnote: Optimal cut-off levels for parameters included in the Cox proportional hazard methods were identified using time-dependent
receiver operating characteristic analysis [16]. The selection of variables for the multivariate model was based on univariate statistical significance
<0.1 followed by redundancy analysis and a forward stepwise algorithm.
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for comparison, 39% of patients had idiopathic PAH, 4%
had familial (heritable) PAH, 15% had APAH-CTD, 11%
had APAH-CHD, 9.5% had PAH associated with anorexi-
gen use, 9.5% had portal hypertension associated PAH and
6.2% had human immunodeficiency virus-associated PAH
[5]. In the Czech cohort of incident cases, APAH-CHD
accounted for a greater proportion of PAH diagnoses than
seen in the prevalent population. One explanation for the
increased diagnosis rate of APAH-CHD is that effective
PAH therapies were available in 2007 for this subgroupthat had not been available at the earlier part of the study.
It is possible that clinicians were more likely to refer pa-
tients for a PAH investigation once suitable therapy had
become available.
As seen in previous registries, almost two-thirds of
PAH patients were female with the mean age of diagno-
sis in the Czech population being approximately 52 years.
The mean age was 10 years higher in the incident popu-
lation than in the prevalent population, which seems to
be a characteristic of the patient populations included in
several contemporary registries [8]. This is unlikely to
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to be a consequence of increased awareness of PAH and
the availability of effective PAH therapies which could
result in the consideration of a PAH diagnosis. Overall,
patients had experienced PAH symptoms for over 3 years
(mean 38 months) before a diagnosis was made, al-
though this varied depending on PAH etiology. The
trend towards shortening the time between the first sign
of symptoms and diagnosis of APAH-CTD incident pa-
tients may result from the introduction of a systematic
PAH screening program in patients with systemic scler-
osis in 2007 and who are, therefore, at risk of APAH-
CTD. The longer duration before diagnosis in patients
with heritable PAH or APAH-CHD may be explained by
their potentially long history of relevant symptoms with
many experiencing fatigue or dyspnea since childhood
and some patients never being completely asymptom-
atic; however this does have to be balanced with the in-
creased suspicion of PAH in these patient groups.
Hemodynamic characteristics of the Czech population
The hemodynamic parameters in Czech patients were
characterized by severe precapillary pulmonary hyper-
tension with low cardiac output and high pulmonary
arteriolar resistance. Similar to other registries, the inci-
dence of patients with positive vasoreactivity was low
and might be related to late diagnosis and advanced dis-
ease. The low incidence of patients with positive vasor-
eactivity may also be related to the higher proportion of
patients with PAH-CHD in the Czech registry (20.4%);
data from the French registry have previously shown
that patients with PAH-CHD have a lower probability of
vasoreactivity versus patients with idiopathic PAH [5].
Incident cases on average were classified with more se-
vere NYHA FC (although this was not significant) and
patients were generally older than prevalent cases. How-
ever, their hemodynamics were typically better or com-
parable to the prevalent cases. A possible explanation
for this is that the prevalent patients, despite poorer
hemodynamics, have a better NYHA FC, as they are sur-
vivors and might be better adapted to respond, or are
better responders to PAH-specific therapies. French
registry data also found prevalent cases to typically have
higher mPAP, but lower FC compared with incident
cases [5].
Survival of PAH patients in the Czech Republic
To date, this is the first representative study in the Eastern
Europe that describes the survival rates of patient with
PAH. Survival of PAH patients has been estimated in
other national registries in the USA, Western Europe,
China and Australia, but caution must be taken when
comparing epidemiological data from different countries
as the methodology can be variable. In the Registry toEvaluate Early and Long-term PAH Disease Management
(REVEAL), 1-year survival in the combined incident/
prevalent population of patients with idiopathic or herit-
able PAH was 91.0% (95% CI 89.9–92.1%) [17]. In the inci-
dent cohort of patients with idiopathic, heritable or
anorexigen-associated PAH in the French registry, the sur-
vival estimate at 1 year was 86% and at 3 years was 55%
[18]. In a registry of incident patients in UK and Ireland,
the 1 and 3-year survival rates were 93% and 73%, respect-
ively [9]. In the Czech analysis, lower survival in the over-
all PAH patient cohort was associated with higher age and
lower creatinine clearance. The analysis showing that the
patients with lower creatinine levels had significantly
lower right atrial pressure versus patients with higher cre-
atinine levels might, in part, explain why this was associ-
ated with survival. Patients with APAH-CHD also had the
best prognosis when compared with patients with idio-
pathic or heritable PAH. These findings confirm previous
analyses and the importance of PAH etiology on patient
outcomes [19-21].
The limitations of the retrospective data from our ob-
servational study should be acknowledged. These in-
clude the potential loss of patients to follow-up and the
difficulty defining the time of diagnosis in prevalent pa-
tients. It is also important to note that only expert cen-
ters were included in the registry and, therefore, some
patients in the early stages of PAH may have been ex-
cluded. However, the well-defined process for PAH diag-
nosis in the Czech Republic is a definite strength of the
study, as it allowed us to study the epidemiology of PAH
during a period when considerable advances in PAH
diagnosis were occurring. It should also be noted that
due to the advances in diagnosis during this period and
the increase in incident cases since 2007, the prevalence
of PAH in the Czech Republic will need to be reevalu-
ated in the near future.
Conclusion
This is the first epidemiological study of PAH in the
Czech Republic in the modern treatment era, increasing
the knowledge on the epidemiology of PAH worldwide.
It confirms that diagnosis of PAH is frequently made late
in the disease continuum so that patients have signifi-
cant functional impairment. Survival rates were similar
to those seen in previous studies and shorter survival
rates were observed in patients over the age of 60 years
at the time of diagnosis with low creatinine levels. As
the registry is ongoing it will continue to provide clini-
cians with data that will be valuable when managing
PAH patients in the Czech Republic.
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